Flot1, also known as Flotillin-1, is a scaffold protein of lipid rafts. It is involved in multiple biological processes such as lipid raft protein-dependent or clathrin-independent endocytosis, and the formation of hippocampal synapses. It participates in signaling transduction and vesicular trafficking pathways, playing a significant role in normal physiological functions and disease development [2].

FLOT1 has been found to have a profound impact on cancer progression. In gastric cancer, FLOT1 promotes cell progression and metastasis by interacting with BCAR1 through the ERK signaling pathway [1]. In lung adenocarcinoma, it promotes tumor development, induces epithelial-mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway [5]. In acute myeloid leukemia (AML), increased FLOT1 expression is correlated with poor clinical outcome, and its knockdown inhibits AML cell growth through triggering apoptosis and pyroptosis [4]. In glioblastoma, the SDC1-TGM2-FLOT1-BHMT complex influences the fusion of autophagosomes with lysosomes, determining radiosensitivity [3]. In esophageal cancer, interfering with Circ_0003855 expression, which is related to miR-622 and FLOT1, can inhibit the activity of cancer cells [6]. In ovarian cancer, FLOT1 is a novel serum biomarker, and its mRNA m6A modification can be targeted for inhibition [7].

In conclusion, FLOT1 is crucial in multiple biological processes, especially in cancer-related pathways. The findings from various disease-related studies highlight its potential as a therapeutic target and biomarker. Understanding the role of FLOT1 through functional studies, including gene knockout models if applicable in these disease areas, can provide new insights into disease mechanisms and treatment strategies.